Sangamo Therapeutics, Inc. reports impairment charges for the three months ended September 30, 2023. For the quarter, Impairment of long-lived assets was $44.8 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5234 USD | +4.18% | +0.27% | -3.66% |
05-09 | Earnings Flash (SGMO) SANGAMO THERAPEUTICS Reports Q1 Revenue $481,000 | MT |
03-22 | Sangamo Therapeutics Prices $24 Million Registered Direct Offering | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.66% | 104M | |
+2.97% | 108B | |
+10.21% | 105B | |
+1.57% | 23.46B | |
-12.77% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.50% | 17.19B | |
+6.00% | 13.99B | |
+37.20% | 12.53B |
- Stock Market
- Equities
- SGMO Stock
- News Sangamo Therapeutics, Inc.
- Sangamo Therapeutics, Inc. Reports Impairment Charges for the Three Months Ended September 30, 2023